- Home
- PLBC vs ENLV Comparison
PLBC vs ENLV Comparison
Compare PLBC & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLBC | ENLV |
|---|---|---|
| Founded | 1980 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 258.7M |
| IPO Year | 2002 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PLBC | ENLV |
|---|---|---|
| Price | $47.54 | $1.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $55.50 | $13.00 |
| AVG Volume (30 Days) | 34.6K | ★ 199.5K |
| Earning Date | 04-15-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.54 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.59 | N/A |
| Revenue Next Year | $5.15 | N/A |
| P/E Ratio | $16.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.71 | $0.66 |
| 52 Week High | $54.58 | $2.10 |
Technical Indicators
Market Signals| Indicator | PLBC | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 34.96 | 42.89 |
| Support Level | $40.95 | $1.00 |
| Resistance Level | $49.24 | $1.23 |
| Average True Range (ATR) | 1.29 | 0.06 |
| MACD | -0.35 | -0.01 |
| Stochastic Oscillator | 17.40 | 2.78 |
Price Performance
Historical ComparisonAbout PLBC Plumas Bancorp
Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.